The FDA just approved the first transdermal one-a-day anti-depressant: Emsam, an MAO inhibitor. In theory, this patch allows patients to continue eating the foods that they enjoy — at least at the lowest dose, which they wouldn’t be able to do with a tablet. Higher strengths allow no such luxury.
With the amazing assortment of drug interactions that MAOIs have, I question whether this is really beneficial for anyone. I can honestly say that I’ve seen one prescription for an MAOI in the last three years. With the advent of safer anti-depressants — the SSRIs — and the rightfully-earned stigma against MAO inhibitors, I wonder if Emsam really has a market. Sure there will be some sales, but given that it costs ~$500 million to bring a new drug to market, will it recoup its own R&D costs before its patent expires?
[tags]selegiline, MAO inhibitors, Emsam, SSRIs, anti-depressants[/tags]